Medi-570 0.1 mg (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
49 | Systemic lupus erythematosus | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01127321 (ClinicalTrials.gov) | May 2010 | 14/4/2010 | A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus | A Phase 1, Double-blind, Randomized, Single Ascending Dose Study of the Safety and Tolerability of MEDI-570 in SLE | Lupus Erythematosus, Systemic | Other: Placebo;Biological: MEDI-570 0.03 MG;Biological: MEDI-570 0.1 MG;Biological: MEDI-570 0.3 MG;Biological: MEDI-570 1 MG | MedImmune LLC | AstraZeneca | Terminated | 18 Years | N/A | All | 44 | Phase 1 | United States;Canada;Mexico;Peru;South Africa |